MedTrace Logo

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

NCT00552188 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2013-08-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

VIA-2291

100 mg, oral dosing, 1 time daily for 24 weeks

DRUG

Placebo

oral dosing, 1 time daily for 24 weeks

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • Icahn School of Medicine at Mount Sinai

    collaborator OTHER

  • University of Massachusetts, Worcester

    collaborator OTHER

  • Winthrop University Hospital

    collaborator OTHER

  • Montreal Heart Institute

    collaborator OTHER

  • Tallikut Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Rebecca Taub, MD · VIA Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00552188 on ClinicalTrials.gov